Cell Genesys to acquire Somatix for $250 mil.; combined company will have five development programs.
CELL GENESYS $250 MIL. ACQUISITION OF SOMATIX WILL BUILD "GENE THERAPY POWERHOUSE," Cell Genesys CEO Stephen Sherwin, MD, declared in a Jan. 13 teleconference held to announce the signing of a definitive merger agreement. The combined company will have five gene therapy programs in development and the "largest patent portfolio in the gene therapy area," Sherwin maintained. The deal is expected to close in April.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth